Apotex Seeks $4 Bil. Bond From Sanofi/Bristol At Plavix Injunction Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
During an Aug. 18 hearing, Apotex says a preliminary injunction should not include a recall of generic clopidogrel.
You may also be interested in...
Plavix Patent Infringement Trial Set For Jan. 22
Sanofi/Bristol demonstrated that Apotex patent invalidity defense "lacks substantial merit," according to a court ruling granting a preliminary injunction blocking generics.
Plavix Patent Infringement Trial Set For Jan. 22
Sanofi/Bristol demonstrated that Apotex patent invalidity defense "lacks substantial merit," according to a court ruling granting a preliminary injunction blocking generics.
Plavix Injunction Ruling Will Include Irreparable Harm Interpretation
If a preliminary injunction is granted, Apotex says it would suffer irreparable harm of $4 bil.; Sanofi/Bristol counter it would be only $25 mil.